Report of Foreign Issuer (6-k)
04 May 2018 - 4:35AM
Edgar (US Regulatory)
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934
For
period ending
03 May
2018
GlaxoSmithKline plc
(Name
of registrant)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or
will
file annual reports under cover Form 20-F or Form 40-F
Form
20-F x Form 40-F
--
Indicate
by check mark whether the registrant by furnishing the
information
contained in this Form is also thereby furnishing the
information
to the Commission pursuant to Rule 12g3-2(b) under the
Securities
Exchange Act of 1934.
Yes
No x
GlaxoSmithKline
plc
Result of Annual General Meeting
GlaxoSmithKline plc ('GSK') announces that at its
Annual General Meeting ('AGM') today, all resolutions were passed
by shareholders. The full text of each resolution is contained in
the 2018 Notice of AGM which is available on the GSK website
at
www.gsk.com
.
GSK
AGM Poll Results
The
following table shows the total number of votes cast for each
resolution:
Resolution
|
Total votes for
*
|
%
|
Total votes against
|
%
|
Total votes cast
|
Votes withheld
**
|
1
|
Receive
and adopt the 2017 Annual Report
|
3,774,060,035
|
96.85
|
122,642,168
|
3.15
|
3,896,702,203
|
9,102,585
|
2
|
Approve
the Annual report on remuneration
|
2,851,170,418
|
90.41
|
302,423,307
|
9.59
|
3,153,593,725
|
752,204,847
|
3
|
Election
of Dr Hal Barron
|
3,881,663,314
|
99.53
|
18,181,557
|
0.47
|
3,899,844,871
|
5,937,889
|
4
|
Election
of Dr Laurie Glimcher
|
3,886,364,801
|
99.64
|
13,925,416
|
0.36
|
3,900,290,217
|
5,484,445
|
5
|
Re-election
of Philip Hampton
|
3,880,514,761
|
99.49
|
19,714,243
|
0.51
|
3,900,229,004
|
5,551,448
|
6
|
Re-election
of Emma Walmsley
|
3,885,288,493
|
99.61
|
15,236,656
|
0.39
|
3,900,525,149
|
5,261,280
|
7
|
Re-election
of Vindi Banga
|
3,874,981,084
|
99.37
|
24,610,295
|
0.63
|
3,899,591,379
|
6,184,729
|
8
|
Re-election
of Dr Vivienne Cox
|
3,784,417,872
|
97.05
|
114,935,231
|
2.95
|
3,899,353,103
|
6,421,540
|
9
|
Re-election
of Simon Dingemans
|
3,826,327,989
|
98.12
|
73,437,843
|
1.88
|
3,899,765,832
|
6,009,962
|
10
|
Re-election
of Lynn Elsenhans
|
3,877,253,828
|
99.41
|
23,041,318
|
0.59
|
3,900,295,146
|
5,478,806
|
11
|
Re-election
of Dr Jesse Goodman
|
3,886,003,347
|
99.63
|
14,266,676
|
0.37
|
3,900,270,023
|
5,506,284
|
12
|
Re-election
of Judy Lewent
|
3,794,070,532
|
97.29
|
105,710,801
|
2.71
|
3,899,781,333
|
5,994,672
|
13
|
Re-election
of Urs Rohner
|
3,871,948,993
|
99.29
|
27,625,403
|
0.71
|
3,899,574,396
|
6,201,911
|
14
|
Appointment
of Deloitte LLP as the auditors
|
3,892,781,525
|
99.79
|
8,074,204
|
0.21
|
3,900,855,729
|
4,930,709
|
15
|
Remuneration
of auditors
|
3,889,076,112
|
99.71
|
11,291,626
|
0.29
|
3,900,367,738
|
5,413,277
|
16
|
Authority
for the company to make donations to political organisations and
incur political expenditure
|
3,814,639,515
|
97.86
|
83,559,851
|
2.14
|
3,898,199,366
|
7,600,333
|
17
|
Authority
to allot shares
|
3,749,621,504
|
96.23
|
147,032,649
|
3.77
|
3,896,654,153
|
9,128,625
|
18
|
Disapplication
of pre-emption rights - general power
***
|
3,792,164,960
|
97.38
|
101,981,885
|
2.62
|
3,894,146,845
|
11,614,736
|
19
|
Disapplication
of pre-emption rights - in connection with an acquisition or
specified capital investment
***
|
3,675,122,062
|
94.36
|
219,534,966
|
5.64
|
3,894,657,028
|
11,110,220
|
20
|
Authority
for the company to purchase its own shares
***
|
3,834,088,739
|
98.40
|
62,147,383
|
1.60
|
3,896,236,122
|
9,555,694
|
21
|
Exemption
from statement of senior statutory auditor's name
|
3,864,323,350
|
99.16
|
32,625,496
|
0.84
|
3,896,948,846
|
8,825,695
|
22
|
Authority
for reduced notice of a general meeting other than an
AGM
***
|
3,641,775,376
|
93.45
|
255,347,155
|
6.55
|
3,897,122,531
|
8,662,254
|
23
|
Approve
the adoption of new Articles of Association
***
|
3,883,973,088
|
99.79
|
8,108,271
|
0.21
|
3,892,081,359
|
11,790,307
|
Notes:
*
|
Includes
discretionary votes.
|
**
|
A vote
withheld is not a vote in law and is not counted in the calculation
of the proportion of votes "For" or "Against" a
resolution.
|
***
|
Indicates
Special Resolutions requiring a 75% majority.
|
The above poll results will shortly be available
on the company's website at
www.gsk.com
.
In accordance with Listing Rule 9.6.2, a copy of
the resolutions, other than those concerning ordinary business,
will be submitted to the UK Listing Authority and will in due
course be available for inspection at
www.morningstar.co.uk/uk/NSM
Professor Sir Roy
Anderson did not stand for re-election as a Director and retired
from the Board with effect from the conclusion of the
AGM.
In
accordance with section 430(2B) of the Companies Act 2006, GSK
confirms that Professor Sir Roy Anderson will receive payment of
fees for service whilst a Director but no other remuneration
payment or payment for loss of office will be made in connection
with his departure.
The
following table provides further relevant information:
|
GSK's
Eighteen
AGM
(2018)
|
GSK's
Seventeenth
AGM
(2017)
|
Issued
share capital (excluding Treasury Shares)
|
4,959,302,644
|
4,917,502,476
|
Total
votes cast and votes withheld lodged as a % of GSK's issued share
capital (excluding Treasury Shares)
|
78.76%
|
74.43%
|
Total
shareholder population
|
112,326
|
116,502
|
Total
number of proxies lodged
|
6,931
|
7,336
|
% of
shareholders who lodged proxies
|
6.17%
|
6.30%
|
Number
of shareholders, corporate representatives and proxies who attended
the AGM
|
415
|
435
|
V
A Whyte
Company
Secretary
3 May
2018
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
GlaxoSmithKline plc
|
|
(Registrant)
|
|
|
Date: May
03,2018
|
|
|
|
|
By: VICTORIA
WHYTE
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GlaxoSmithKline plc
|
GSK (NYSE:GSK)
Historical Stock Chart
From Oct 2024 to Nov 2024
GSK (NYSE:GSK)
Historical Stock Chart
From Nov 2023 to Nov 2024